Glenmark Gets CDSCO Panel Nod to study Indacaterol, Glycopyrrolate,Mometasone Furoate FDC drug
New Delhi: The drug major Glenmark has got a go-ahead from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to conduct the Phase IV clinical trial of the fixed-dose combination (FDC) capsule containing Indacaterol (as acetate) equivalent to Indacaterol 150 mcg plus Glycopyrrolate IP equivalent to glycopyrronium 50 mcg plus Mometasone Furoate IP 160 mcg Dry Powder for inhalation.
This came after the drug major Glenmark presented the Phase IV clinical trial protocol of the FDC pulmonary drug each capsule containing Indacaterol (as acetate) plus Glycopyrrolate IP plus MometasoneFuroate IP 160 mcg Dry Powder for inhalation before the committee.
Indacaterol is an inhaled long-acting beta-2 adrenergic agonist used to relax bronchial smooth muscle and improve symptoms and airflow obstruction caused by Chronic Obstructive Pulmonary Disease (COPD) and moderate to severe asthma.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.